Hiroshi Hongo

817 total citations
74 papers, 511 citations indexed

About

Hiroshi Hongo is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Surgery. According to data from OpenAlex, Hiroshi Hongo has authored 74 papers receiving a total of 511 indexed citations (citations by other indexed papers that have themselves been cited), including 50 papers in Pulmonary and Respiratory Medicine, 20 papers in Oncology and 18 papers in Surgery. Recurrent topics in Hiroshi Hongo's work include Prostate Cancer Treatment and Research (37 papers), Prostate Cancer Diagnosis and Treatment (10 papers) and Radiopharmaceutical Chemistry and Applications (8 papers). Hiroshi Hongo is often cited by papers focused on Prostate Cancer Treatment and Research (37 papers), Prostate Cancer Diagnosis and Treatment (10 papers) and Radiopharmaceutical Chemistry and Applications (8 papers). Hiroshi Hongo collaborates with scholars based in Japan, United Kingdom and United States. Hiroshi Hongo's co-authors include Takeo Kosaka, Mototsugu Oya, Shuji Mikami, Ryuichi Mizuno, Eiji Kikuchi, Hiroshi Nishihara, Yasumasa Miyazaki, Akira Miyajima, Kazuhiro Matsumoto and Eriko Aimono and has published in prestigious journals such as Nature Communications, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Hiroshi Hongo

68 papers receiving 504 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Hiroshi Hongo Japan 13 274 169 119 108 80 74 511
David H. Hwang United States 12 211 0.8× 174 1.0× 128 1.1× 96 0.9× 67 0.8× 21 480
Li Yan Khor Singapore 11 272 1.0× 173 1.0× 114 1.0× 94 0.9× 91 1.1× 36 470
Hironori Betsunoh Japan 11 112 0.4× 153 0.9× 103 0.9× 70 0.6× 66 0.8× 24 362
Marta Batus United States 13 243 0.9× 178 1.1× 296 2.5× 83 0.8× 30 0.4× 60 569
Masayuki Shitara Japan 16 212 0.8× 231 1.4× 150 1.3× 104 1.0× 50 0.6× 30 464
Yingyi Zhang China 10 155 0.6× 117 0.7× 114 1.0× 45 0.4× 58 0.7× 21 448
Nikolaos Syrigos Greece 12 190 0.7× 187 1.1× 279 2.3× 91 0.8× 42 0.5× 61 599
Krzysztof Leśniewski-Kmak Poland 11 148 0.5× 121 0.7× 256 2.2× 57 0.5× 31 0.4× 31 477
Alexander Meisel Switzerland 12 102 0.4× 147 0.9× 183 1.5× 88 0.8× 51 0.6× 27 486
Yukari Ishiguro Japan 12 91 0.3× 148 0.9× 138 1.2× 59 0.5× 86 1.1× 19 364

Countries citing papers authored by Hiroshi Hongo

Since Specialization
Citations

This map shows the geographic impact of Hiroshi Hongo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hiroshi Hongo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hiroshi Hongo more than expected).

Fields of papers citing papers by Hiroshi Hongo

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Hiroshi Hongo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hiroshi Hongo. The network helps show where Hiroshi Hongo may publish in the future.

Co-authorship network of co-authors of Hiroshi Hongo

This figure shows the co-authorship network connecting the top 25 collaborators of Hiroshi Hongo. A scholar is included among the top collaborators of Hiroshi Hongo based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Hiroshi Hongo. Hiroshi Hongo is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Shigeta, Keisuke, Hiroshi Hongo, Sheng‐Yu Ku, et al.. (2025). MUC1-C dependence in treatment-resistant prostate cancer uncovers a target for antibody-drug conjugate therapy. JCI Insight. 10(14). 1 indexed citations
2.
Hamamura, Yuki, Hiroshi Hongo, Etsu Tashiro, et al.. (2024). Selective killing of castration‐resistant prostate cancer cells by formycin A via the ATF4–CHOP axis. Cancer Science. 115(12). 3997–4007. 1 indexed citations
3.
Komori, Takahiro, Takeo Kosaka, Keitaro Watanabe, et al.. (2022). Salvage focal brachytherapy in castration‐resistant prostate cancer with neuroendocrine differentiation after radiation therapy. IJU Case Reports. 5(4). 233–236. 2 indexed citations
4.
Kosaka, Takeo, Kohei Nakamura, Hiroshi Hongo, et al.. (2022). Multiple metastases of androgen indifferent prostate cancer in the urinary tract: two case reports and a literature review. BMC Medical Genomics. 15(1). 118–118. 5 indexed citations
5.
Kosaka, Takeo, Yota Yasumizu, Hiroshi Hongo, et al.. (2022). Characterizing cyclin-dependent kinase 12(CDK12)-altered aggressive prostate cancer: a twelve-case series. International Journal of Clinical Oncology. 27(12). 1867–1873.
6.
Takayama, Ken‐ichi, Takeo Kosaka, Takashi Suzuki, et al.. (2021). Subtype-specific collaborative transcription factor networks are promoted by OCT4 in the progression of prostate cancer. Nature Communications. 12(1). 3766–3766. 30 indexed citations
7.
Kobayashi, Hiroaki, Takeo Kosaka, Shuji Mikami, et al.. (2021). Vasohibin-1 expression as a biomarker of aggressive nature in ductal adenocarcinoma of the prostate: a retrospective cohort study at two centres in Japan. BMJ Open. 11(11). e056439–e056439. 4 indexed citations
8.
Hongo, Hiroshi, Takeo Kosaka, Eriko Aimono, Hiroshi Nishihara, & Mototsugu Oya. (2020). Aggressive prostate cancer with somatic loss of the homologous recombination repair gene FANCA: a case report. Diagnostic Pathology. 15(1). 5–5. 6 indexed citations
9.
Niwa, Naoya, Nobuyuki Tanaka, Hiroshi Hongo, et al.. (2019). TNFAIP2 expression induces epithelial-to-mesenchymal transition and confers platinum resistance in urothelial cancer cells. Laboratory Investigation. 99(11). 1702–1713. 20 indexed citations
10.
11.
Shigeta, Keisuke, Takeo Kosaka, Hiroshi Hongo, et al.. (2019). Castration-resistant prostate cancer patients who had poor response on first androgen deprivation therapy would obtain certain clinical benefit from early docetaxel administration. International Journal of Clinical Oncology. 24(5). 546–553. 9 indexed citations
12.
13.
Natsuaki, Masahiro, Hiroshi Hongo, Tetsuya Kaneko, et al.. (2019). Spontaneous Internal Mammary Artery Graft Dissection Triggered by Emotional Stress. SHILAP Revista de lepidopterología. 1(5). 732–736. 1 indexed citations
14.
Kosaka, Takeo, Hiroshi Hongo, Keitaro Watanabe, et al.. (2018). No significant impact of patient age and prior treatment profile with docetaxel on the efficacy of cabazitaxel in patient with castration-resistant prostate cancer. Cancer Chemotherapy and Pharmacology. 82(6). 1061–1066. 11 indexed citations
15.
Ogihara, Koichiro, Takeo Kosaka, Eiji Kikuchi, et al.. (2015). Spontaneous Regression of Epstein-Barr Virus-Positive Primary Diffuse Large Cell B-Cell Lymphoma of the Urinary Bladder After the Cessation of Enzalutamide. Clinical Genitourinary Cancer. 14(2). e215–e218. 4 indexed citations
16.
Niwa, Naoya, et al.. (2014). Mucosa-associated lymphoid tissue lymphoma arising from the kidney. Canadian Urological Association Journal. 8(1-2). 86–86. 3 indexed citations
17.
Kuroda, Yutaka, et al.. (2001). Internal echo histogram examination has a role in distinguishing malignant tumors from benign masses in the breast. Clinical Imaging. 25(3). 151–153. 2 indexed citations
18.
Hironaka, Mitsugu, et al.. (1986). A case of primary clear cell adenocarcinoma of the lung with a high serum level of CEA.. Haigan. 26(2). 203–208.
19.
Kamei, Toshiaki, et al.. (1985). Primary gastric choriocarcinoma associated with adenocarcinoma－A Case Report with Immunohistochemical Study－. 32(1). 11–19. 1 indexed citations
20.
Hongo, Hiroshi, et al.. (1963). Eosinophilic Granuloma of the Ishium. Nagasaki University's Academic Output SITE (Nagasaki University). 7(3). 69–75.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by David H. Hwang Breakdown of academic impact, for papers by Li Yan Khor Breakdown of academic impact, for papers by Hironori Betsunoh Breakdown of academic impact, for papers by Marta Batus Breakdown of academic impact, for papers by Masayuki Shitara Breakdown of academic impact, for papers by Yingyi Zhang Breakdown of academic impact, for papers by Nikolaos Syrigos Breakdown of academic impact, for papers by Krzysztof Leśniewski-Kmak Breakdown of academic impact, for papers by Alexander Meisel Breakdown of academic impact, for papers by Yukari Ishiguro
Rankless by CCL
2026